{
  "ticker": "CYP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974377",
  "id": "02974377",
  "pages": 9,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0945",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m9jv66vrf945.pdf",
  "summary": "### **Key Material Information Summary (Quarterly Activity Report - Cynata Therapeutics, 30 July 2025)**  \n\n#### **Clinical Trial Progress:**  \n- **Phase 2 aGvHD trial**: >75% enrolled, primary results expected H1 2026.  \n- **Phase 3 Osteoarthritis (SCUlpTOR)**: Fully enrolled (321 patients), top-line results expected Feb-Apr 2026.  \n- **Kidney transplant trial (Cohort 1)**: Treatment completed; DSMB review expected Q4 2025.  \n\n#### **Financial Position:**  \n- **Cash balance**: $5.0m (as of 30 June 2025).  \n- **Expected R&D tax rebate**: ~$1.25m (incoming).  \n- **Funding runway**: Extended to mid-2026 (covers key clinical readouts).  \n\n#### **Preclinical/Commercial Highlights:**  \n- **Diabetic Foot Ulcers (Phase 1)**: 83.6% wound reduction vs. 47.8% standard care.  \n- **Ischaemic Heart Disease (Preclinical)**: Positive data showing improved cardiac function.  \n\n#### **Upcoming Catalysts:**  \n- Phase 2/3 readouts (aGvHD, Osteoarthritis) and kidney trial DSMB review in 2025\u20132026.  \n\n#### **Cash Flow Notes:**  \n- Net operating cash outflow: $3.5m (quarter).  \n- Milestone-driven payments ($1.9m in quarter) skew near-term cash burn; future quarters expected to be lower.  \n\n**No material capital raising or corporate actions identified.**",
  "usage": {
    "prompt_tokens": 6248,
    "completion_tokens": 345,
    "total_tokens": 6593,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T00:01:58.377971"
}